These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 11945163)

  • 1. Applications of artificial neural network in AIDS research and therapy.
    Sardari S; Sardari D
    Curr Pharm Des; 2002; 8(8):659-70. PubMed ID: 11945163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Basic concepts of artificial neural network (ANN) modeling and its application in pharmaceutical research.
    Agatonovic-Kustrin S; Beresford R
    J Pharm Biomed Anal; 2000 Jun; 22(5):717-27. PubMed ID: 10815714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Basic concepts of artificial neural networks (ANN) modeling in the application to pharmaceutical development.
    Bourquin J; Schmidli H; van Hoogevest P; Leuenberger H
    Pharm Dev Technol; 1997 May; 2(2):95-109. PubMed ID: 9552436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ANN multiscale model of anti-HIV drugs activity vs AIDS prevalence in the US at county level based on information indices of molecular graphs and social networks.
    González-Díaz H; Herrera-Ibatá DM; Duardo-Sánchez A; Munteanu CR; Orbegozo-Medina RA; Pazos A
    J Chem Inf Model; 2014 Mar; 54(3):744-55. PubMed ID: 24521170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mapping chemical structure-activity information of HAART-drug cocktails over complex networks of AIDS epidemiology and socioeconomic data of U.S. counties.
    Herrera-Ibatá DM; Pazos A; Orbegozo-Medina RA; Romero-Durán FJ; González-Díaz H
    Biosystems; 2015 Jun; 132-133():20-34. PubMed ID: 25916548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overview of artificial neural networks.
    Zou J; Han Y; So SS
    Methods Mol Biol; 2008; 458():15-23. PubMed ID: 19065803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Classification and quantitation of 1H NMR spectra of alditols binary mixtures using artificial neural networks.
    Amendolia SR; Doppiu A; Ganadu ML; Lubinu G
    Anal Chem; 1998 Apr; 70(7):1249-54. PubMed ID: 9553490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Artificial neural networks as alternative tool for minimizing error predictions in manufacturing ultradeformable nanoliposome formulations.
    León Blanco JM; González-R PL; Arroyo García CM; Cózar-Bernal MJ; Calle Suárez M; Canca Ortiz D; Rabasco Álvarez AM; González Rodríguez ML
    Drug Dev Ind Pharm; 2018 Jan; 44(1):135-143. PubMed ID: 28967285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modeling drug solubility in water-cosolvent mixtures using an artificial neural network.
    Jouyban A; Majidi MR; Jalilzadeh H; Asadpour-Zeynali K
    Farmaco; 2004 Jun; 59(6):505-12. PubMed ID: 15178314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dexamethasone-releasing cochlear implant coatings: application of artificial neural networks for modelling of formulation parameters and drug release profile.
    Nemati P; Imani M; Farahmandghavi F; Mirzadeh H; Marzban-Rad E; Nasrabadi AM
    J Pharm Pharmacol; 2013 Aug; 65(8):1145-57. PubMed ID: 23837582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neural networks in analytical chemistry.
    Jalali-Heravi M
    Methods Mol Biol; 2008; 458():81-121. PubMed ID: 19065807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Artificial neural networks in the optimization of a nimodipine controlled release tablet formulation.
    Barmpalexis P; Kanaze FI; Kachrimanis K; Georgarakis E
    Eur J Pharm Biopharm; 2010 Feb; 74(2):316-23. PubMed ID: 19815063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. What can artificial neural networks teach us about neurodegenerative disorders with extrapyramidal features?
    Litvan I; DeLeo JM; Hauw JJ; Daniel SE; Jellinger K; McKee A; Dickson D; Horoupian DS; Lantos PL; Tabaton M
    Brain; 1996 Jun; 119 ( Pt 3)():831-9. PubMed ID: 8673495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Application of an artificial neural network in the design of sustained-release dosage forms].
    Wei XH; Wu JJ; Liang WQ
    Yao Xue Xue Bao; 2001 Sep; 36(9):690-4. PubMed ID: 12580110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Artificial neural networks applied to the in vitro-in vivo correlation of an extended-release formulation: initial trials and experience.
    Dowell JA; Hussain A; Devane J; Young D
    J Pharm Sci; 1999 Jan; 88(1):154-60. PubMed ID: 9874718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autonomous design of artificial neural networks by Neurex.
    Michaud F; Gonzales Rubio R
    Neural Comput; 1996 Nov; 8(8):1767-86. PubMed ID: 8888617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmaceutical fingerprinting: evaluation of neural networks and chemometric techniques for distinguishing among same-product manufacturers.
    Welsh WJ; Lin W; Tersigni SH; Collantes E; Duta R; Carey MS; Zielinski WL; Brower J; Spencer JA; Layloff TP
    Anal Chem; 1996 Oct; 68(19):3473-82. PubMed ID: 8843143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of descriptor vector scaling on the classification of drugs and nondrugs with artificial neural networks.
    Givehchi A; Schneider G
    J Mol Model; 2004 Jun; 10(3):204-11. PubMed ID: 15067522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimization of controlled release nanoparticle formulation of verapamil hydrochloride using artificial neural networks with genetic algorithm and response surface methodology.
    Li Y; Abbaspour MR; Grootendorst PV; Rauth AM; Wu XY
    Eur J Pharm Biopharm; 2015 Aug; 94():170-9. PubMed ID: 25986587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Application of neural computing in pharmaceutical product development.
    Hussain AS; Yu XQ; Johnson RD
    Pharm Res; 1991 Oct; 8(10):1248-52. PubMed ID: 1796042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.